Katie Adams

Cooley advised Fluidstack, a premier artificial intelligence cloud platform, on its two 10-year high-performance computing colocation agreements with TeraWulf, including a 30-day expansion option at TeraWulf's Lake Mariner data center campus in Western New York.

Cooley advised CallTower, an international leader in delivering cloud-based, enterprise-class communications, contact center and collaboration solutions, on its investment from BV Investment Partners.

Cooley advised Midwestern Electric, a portfolio company of Canada-based private equity firm CAI Capital Partners and a provider of electrical infrastructure services, on its acquisition of Kuharchik Construction and Wyoming Electric & Signals.

A Cooley team advised Horizon Therapeutics, a specialty biopharmaceutical company, on its agreement to be acquired by Amgen. The approximately $28 billion merger would represent the third-largest all-cash transaction in the pharmaceutical sector in history and the biggest healthcare deal of 2022.

Cooley advised Asymchem, a Chinese-based contract development and manufacturing company serving the global pharmaceutical and biotech industry, on its definitive agreement to acquire Snapdragon Chemistry, a US-based chemical technology company. Partner Yiming Liu led the Cooley team.

As a result of the transaction, Asymchem will significantly expand its footprint in the US, offering customers a seamless path from preclinical process R&D through commercial current good manufacturing practice (cGMP) production. Snapdragon will operate as a stand-alone Asymchem division, and continue with its ongoing lab and manufacturing facility expansion for additional capacity to support larger, pilot-scale manufacturing in Waltham, Massachusetts.

"We believe continuous flow manufacturing is a revolutionary technology and represents the future of pharmaceutical production, not only generating advantages to process safety and cost, but also bringing tremendous environmental benefits," Hao Hong, chairman and CEO of Asymchem, said in a news release. "Asymchem has been deeply committed to flow chemistry technology development and its application expansion in the pharmaceutical industry for more than a decade. We are excited that this strategic acquisition will further strengthen our capabilities in continuous manufacturing, as well as broadening our service scope and client pool."